Paris - Delayed Quote EUR

ABIVAX Société Anonyme (ABVX.PA)

Compare
7.06 0.00 (0.00%)
As of 4:36:20 PM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ABVX.PA

Recent News: ABVX.PA

View More
Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now?

Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now?
Insider Monkey 18 days ago
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
GlobeNewswire last month
Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information
GlobeNewswire last month
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
GlobeNewswire last month
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
GlobeNewswire 2 months ago
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
GlobeNewswire 2 months ago
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
GlobeNewswire 2 months ago
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
GlobeNewswire 2 months ago
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
GlobeNewswire 2 months ago
Abivax presents first-half 2024 financial results

Abivax presents first-half 2024 financial results
GlobeNewswire 3 months ago
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
GlobeNewswire 4 months ago
View More

Related Tickers

ALSEN.PA Sensorion SA
0.6200
-0.96%
 
ALQGC.PA Quantum Genomics Société Anonyme
0.0721
0.00%
 
7PO.SG Poxel SA
0.1184
-0.67%
 
4BB.L 4basebio PLC
1,185.00
0.00%
 
HPHA.DE Heidelberg Pharma AG
2.2300
-1.76%
 
ADOC.PA Adocia SA
5.88
+1.38%
 
MDG1.DE Medigene AG
1.0340
+0.39%
 
TNG.PA Transgene SA
0.7010
-0.14%
 
IVA Inventiva S.A.
2.2681
-2.24%
 
IMMU.ST Mendus AB (publ)
8.82
+4.20%